# US 2014/0194467 A1 · Plasma cell disorders > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0194467 A1 - Document ID: US20140194467A1 - Status: Published application - Kind: A1 - Application number: 13/993,834 - Filed: 2011-12-13 - Published: 2014-07-10 - Earliest claimed: 2010-12-13 - Assignees: The University of Sussex - Inventors: Sarah Faith Newbury; Timothy James Telfer Chevassut; Christopher Iain Jones; Maria Vasilyevna Zabolotskaya; Helen Jayne Susan Stewart - Web page: https://patentgrep.com/patent/US20140194467A1 ## CPC - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone - A61P 35/00: Antineoplastic agents - C12Q 1/6883: for diseases caused by alterations of genetic material - C12Q 2600/118: Prognosis of disease development - C12Q 2600/16: Primer sets for multiplex assays - C12Q 2600/178: miRNA, siRNA or ncRNA - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention relates to novel biological markers for plasma cell disorders, such as multiple myeloma, and in particular to the use of microRNAs as diagnostic and prognostic markers in assays for detecting such disorders. The invention also relates to methods of determining the efficacy of treating a plasma cell disorder with a therapeutic agent, and kits for carrying 5 out the assays and methods. The assays are qualitative and/or quantitative, and are adaptable to large-scale screening and clinical trials. ## Claims ### Claim at position 1 1-28. (canceled) ### Claim 29 A method for diagnosing a subject suffering from a plasma cell disorder, or a pre-disposition thereto, or for providing a prognosis of the subject's condition, the method comprising analysing the concentration of one or more type of microRNA molecule in a bodily sample from a test subject and comparing this concentration with a reference for the concentration of the one or more type of microRNA molecule in an individual who does not suffer from a plasma cell disorder, wherein a difference in the concentration of the one or more type of microRNA molecule in the bodily sample from the test subject compared to the reference suggests that the subject is suffering from a plasma cell disorder, or has a pre-disposition thereto, or provides a negative prognosis of the subject's condition. ### Claim 30 (depends on 29) A method according to claim 29, wherein the plasma cell disorder is amyloidosis, Waldenstrom's macroglobulinemia, osteosclerotic myeloma (POEMS syndrome), Monoclonal gammopathy of unknown significance (MGUS) or plasma cell myeloma. ### Claim 31 (depends on 29) A method according to claim 29, wherein the plasma cell disorder is plasma cell myeloma. ### Claim 32 (depends on 29) A method according to claim 29, wherein the method comprises analysing the concentration of one or more type of microRNA molecule selected from the group of miRNA molecules consisting of miRNA-15a, miRNA-15b, miRNA-16, miRNA-221, miRNA-451, miRNA-638, miRNA-720, miRNA-1246, miRNA-1308, miRNA-1915, miRNA-1974, miRNA-574-5p and miRNA-762. ### Claim 33 (depends on 29) A method according to claim 29, wherein the method comprises analysing the concentration of one or more type of microRNA molecule selected from the group of miRNA molecules consisting of miRNA-638, miRNA-720, miRNA-1246, miRNA-1308 and miRNA-1915. ### Claim 34 (depends on 29) A method according to claim 29, wherein the difference in concentration is an increase compared to the reference, and wherein the method comprises analysing the concentration of one or more type of microRNA molecule selected from the group of miRNA molecules consisting of miRNA-15a, miRNA-15b, miRNA-16, miRNA-221, miRNA-638, miRNA-720, miRNA-1246 and miRNA-1915. ### Claim 35 (depends on 34) A method according to claim 34, wherein the increase in concentration of miRNA compared to the reference concentration is at least 5-, 10, 15- or 20-fold higher than the reference concentration. ### Claim 36 (depends on 29) A method according to claim 29, wherein the difference in concentration is a decrease compared to the reference, and wherein the method comprises analysing the concentration of miRNA-451 and/or miRNA 1308. ### Claim 37 (depends on 36) A method according to claim 36, wherein the decrease in concentration of miRNA compared to the reference concentration is at least 5-, 10, 15- or 20-fold lower than the reference concentration. ### Claim 38 (depends on 29) A method according to claim 29, wherein the method comprises determining the concentration of one or more type of microRNA molecule selected from the group of miRNA molecules comprising a nucleotide sequence substantially as set out in any or SEQ ID No.1 to 13, or any of the complementary sequences thereof, or variants or fragments thereof. ### Claim 39 (depends on 29) A method according to claim 29, wherein the bodily sample is a blood plasma sample or a blood serum sample. ### Claim 40 A kit for diagnosing a subject suffering from a plasma cell disorder, or a pre-disposition thereto, or for providing a prognosis of the subject's condition, the kit comprising: (i) means for determining the concentration of one or more type of micro RNA molecule in a sample from a test subject; and (ii) a reference for the concentration of the one or more type of microRNA molecule in a sample from an individual who does not suffer from a plasma cell disorder, wherein the kit is used to identify a difference in the concentration of the one or more type of microRNA molecule in the sample from the test subject compared to the reference concentration, thereby suggesting that the test subject suffers from a plasma cell disorder, or has a pre-disposition thereto, or providing a negative prognosis of the subject's condition. ### Claim 41 (depends on 40) A kit according to claim 40, wherein the kit is for carrying out a method for diagnosing a subject suffering from a plasma cell disorder, or a pre-disposition thereto, or for providing a prognosis of the subject's condition, the method comprising analysing the concentration of one or more type of microRNA molecule in a bodily sample from a test subject and comparing this concentration with a reference for the concentration of the one or more type of microRNA molecule in an individual who does not suffer from a plasma cell disorder, wherein a difference in the concentration of the one or more type of microRNA molecule in the bodily sample from the test subject compared to the reference suggests that the subject is suffering from a plasma cell disorder, or has a pre-disposition thereto, or provides a negative prognosis of the subject's condition. ### Claim 42 (depends on 40) A kit according to claim 40, wherein the kit comprises detection means for determining the concentration of the one or more type of miRNA in the sample once this has been obtained from the subject. ### Claim 43 (depends on 42) A kit according to claim 42, wherein the detection means comprises one or more primer, for use in a PCR method for amplifying the miRNA. ### Claim 44 (depends on 42) A kit according to claim 42, wherein the kit comprises a positive control, which corresponds to total RNA extracted from a sample of a subject having a plasma cell disorder where it has been established that the relevant miRNAs are present at statistically higher levels than normal controls, wherein the positive control comprises a nucleotide sequence substantially as set out in SEQ ID No.1-13, or the complementary sequence thereof, or a variant, or fragment thereof ### Claim 45 (depends on 42) A kit according to claim 42, wherein the kit comprises a negative control, which corresponds to total RNA extracted from a sample of a normal, healthy subject without a plasma cell disorder, where it has previously been established that the relevant miRNAs are not detectable, wherein the negative control comprises a nucleotide sequence substantially as set out in SEQ ID No.14 or 15, or the complementary sequence thereof, or a variant or fragment thereof. ### Claim 46 A method of treating an individual suffering from a plasma cell disorder, said method comprising the steps of: (i) determining the concentration of one or more microRNA molecule in a sample having been obtained from a test subject, wherein a difference in the concentration of the one or more type of microRNA molecule in the bodily sample from the test subject compared to the concentration of the one or more type of microRNA molecule in a sample from an individual who does not suffer from a plasma cell disorder, suggests that the test subject suffers from a plasma cell disorder, or is pre-disposed thereto, or has a negative prognosis; and (ii) administering, to the test subject, a therapeutic agent that prevents, reduces or delays progression of the plasma cell disorder. ### Claim 47 A method for determining the efficacy of treating a subject suffering from a plasma cell disorder with a therapeutic agent, the method comprising analysing the concentration of one or more type of microRNA molecule in a bodily sample from a test subject and comparing this concentration with a reference for the concentration of the one or more type of microRNA molecule in an individual who does not suffer from a plasma cell disorder, wherein a difference in the concentration of the one or more type of microRNA molecule in the bodily sample compared to the reference is indicative of the efficacy of treating the test subject with the therapeutic agent. ### Claim 48 A kit for determining the efficacy of treating a subject suffering from a plasma cell disorder with a therapeutic agent, the kit comprising: (i) means for determining the concentration of one or more type of microRNA molecule in a sample from a test subject; and (ii) a reference for the concentration of the one or more type of microRNA molecule in a sample from an individual who does not suffer from a plasma cell disorder, wherein the kit is used to identify a difference in the concentration of the one or more type of microRNA molecule in the sample from the test subject compared to the reference concentration, the difference in concentration being indicative of the efficacy of treating the test subject with the therapeutic agent.